Masakazu Toi
Experienced in Hyperhidrosis

Masakazu Toi

Nishinomiya-hama, JP 
Experienced in Hyperhidrosis
Nishinomiya-hama, JP 
OverviewLocationsClinical Research

Overview

Masakazu Toi practices in Nishinomiya-hama, Japan. Mr. Toi is rated as an Experienced expert by MediFind in the treatment of Hyperhidrosis. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Agranulocytosis, Mastectomy, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 584 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hyperhidrosis.

Gender
Male

Locations

Nishinomiya-hama, 6638501, Japan
Other Locations
Komagome, Japan
Kyoto, Japan
Tokyo, Japan
Honkomagome, 1138677, Japan
Japan
Bunkyo, Japan
Kawahara, 6068507, Japan
Miyoshi, 7780005, Japan
Sendai, Japan
Sendamachi, 7300052, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 3

584 Total Publications

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Toi's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile